Author

NZ Fard

Observed names: N. Emami Fard, N.Z. Fard, Nahal Fard

Institution: McMaster University

Observed institution: McMaster University

OpenAlex ID: A5111059271

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5

Immunomodulatory effects of Mepolizumab on group 2 innate lymphoid cells in patients with refractory chronic cough and eosinophilic airways disease (MUCOSA)

2025 · Takahiro Matsuyama, Yoshihisa Tokunaga, et al.

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases

Increased Numbers of Group 3 Innate Lymphoid Cells and C-kit-positive ILC2s Expressing IL-17A in Sputum From Severe Asthmatics With Neutrophilic or Mixed Granulocytic Bronchitis

2023 · X. Ju, N. Emami Fard, et al.

The Inability to Limit Autoimmune Pathology Is Associated with COVID-19 Hospital Fatality

2022 · K. Son, R. Jamil, et al.

Works count: 7

Citation count: 58

H-index: 3

I10-index: 2